Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis
© 2024. The Author(s)..
BACKGROUND: No specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6 autoantibodies in >90% of patients with ulcerative colitis (UC). Given that a subset of ICI-induced colitis is similar to UC, we aimed to clarify the relationship between such autoantibodies and ICI-induced colitis.
METHODS: Serum anti-integrin αvβ6 autoantibody levels were compared between 26 patients with ICI-induced colitis and 157 controls. Endoscopic images of ICI-induced colitis were centrally reviewed. Characteristics of anti-integrin αvβ6 autoantibodies in the ICI-induced colitis patients were compared with those of UC patients.
RESULTS: Anti-integrin αvβ6 autoantibodies were found in 8/26 (30.8%) patients with ICI-induced colitis and 3/157 (1.9%) controls (P < 0.001). Patients with anti-integrin αvβ6 autoantibodies had significantly more typical UC endoscopic features than those without the autoantibodies (P < 0.001). Anti-integrin αvβ6 autoantibodies in ICI-induced colitis patients were associated with grade ≥3 colitis (P = 0.001) and steroid resistance (P = 0.005). Anti-integrin αvβ6 autoantibody titers correlated with ICI-induced colitis disease activity. Anti-integrin αvβ6 autoantibodies of ICI-induced colitis exhibited similar characteristics to those of UC.
CONCLUSIONS: Anti-integrin αvβ6 autoantibodies may serve as potential biomarkers for the diagnosis, classification, risk management, and monitoring the disease activity, of ICI-induced colitis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
British journal of cancer - (2024) vom: 09. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yokode, Masataka [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 13.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1038/s41416-024-02647-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369508955 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369508955 | ||
| 003 | DE-627 | ||
| 005 | 20240313234655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240310s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41416-024-02647-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM369508955 | ||
| 035 | |a (NLM)38461170 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yokode, Masataka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: No specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6 autoantibodies in >90% of patients with ulcerative colitis (UC). Given that a subset of ICI-induced colitis is similar to UC, we aimed to clarify the relationship between such autoantibodies and ICI-induced colitis | ||
| 520 | |a METHODS: Serum anti-integrin αvβ6 autoantibody levels were compared between 26 patients with ICI-induced colitis and 157 controls. Endoscopic images of ICI-induced colitis were centrally reviewed. Characteristics of anti-integrin αvβ6 autoantibodies in the ICI-induced colitis patients were compared with those of UC patients | ||
| 520 | |a RESULTS: Anti-integrin αvβ6 autoantibodies were found in 8/26 (30.8%) patients with ICI-induced colitis and 3/157 (1.9%) controls (P < 0.001). Patients with anti-integrin αvβ6 autoantibodies had significantly more typical UC endoscopic features than those without the autoantibodies (P < 0.001). Anti-integrin αvβ6 autoantibodies in ICI-induced colitis patients were associated with grade ≥3 colitis (P = 0.001) and steroid resistance (P = 0.005). Anti-integrin αvβ6 autoantibody titers correlated with ICI-induced colitis disease activity. Anti-integrin αvβ6 autoantibodies of ICI-induced colitis exhibited similar characteristics to those of UC | ||
| 520 | |a CONCLUSIONS: Anti-integrin αvβ6 autoantibodies may serve as potential biomarkers for the diagnosis, classification, risk management, and monitoring the disease activity, of ICI-induced colitis | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Shiokawa, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kawakami, Hisato |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwada, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Nishikawa, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Muramoto, Yuya |e verfasserin |4 aut | |
| 700 | 1 | |a Kitamoto, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Okabe, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Yamazaki, Hajime |e verfasserin |4 aut | |
| 700 | 1 | |a Okamoto, Norihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Morita, Toshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ohno, Kazuya |e verfasserin |4 aut | |
| 700 | 1 | |a Nakanishi, Risa |e verfasserin |4 aut | |
| 700 | 1 | |a Takimoto, Ikuhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Yasuda, Muneji |e verfasserin |4 aut | |
| 700 | 1 | |a Chikugo, Koki |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumoto, Shimpei |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ota, Sakiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Takeharu |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Hirokazu |e verfasserin |4 aut | |
| 700 | 1 | |a Hirano, Tomonori |e verfasserin |4 aut | |
| 700 | 1 | |a Kakiuchi, Nobuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumori, Tomoaki |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Shuji |e verfasserin |4 aut | |
| 700 | 1 | |a Uza, Norimitsu |e verfasserin |4 aut | |
| 700 | 1 | |a Ooi, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Kodama, Yuzo |e verfasserin |4 aut | |
| 700 | 1 | |a Chiba, Tsutomu |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Hidetoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Seno, Hiroshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d 1947 |g (2024) vom: 09. März |w (DE-627)NLM000027537 |x 1532-1827 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:09 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41416-024-02647-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 09 |c 03 | ||